European stocks, US futures lose momentum after vaccine trials stop


FILE – This September 2020 photo provided by Johnson & Johnson shows the single-dose COVID-19 vaccine being developed by the company.

AP

European stocks surged to a low on Tuesday, losing momentum after the stagnation of the coronovirus test as traders awaited earnings from some of the world’s major banks.

0.7% on Monday, Stokes Europe 600 SXXP,
-0.26%
Less than 0.5%.

German DAX DAX,
-0.35%,
French CAC 40 px 1,
-0.39%
And UK FTSE 100 UKX,
-0.34%
Also drowned in early action.

American Stock SPX,
+ 1.64%
During the light Columbus Day holiday, little news was blasted on Monday, including the Tech-Heavy Nasdaq Composite Comp,
+ 2.55%
Rally 2.6% to its third-highest in history. But futures ES00,
-0.41%

NQ00,
-0.14%
Johnson & Johnson was short as JNJ,
+ 0.57%
The test of the coronovirus vaccine was halted on Monday night after an unexplained illness. It is not uncommon for drug makers to stop trials in this way, and stagnation has not been the more serious clinical catch so far.

Results for the third quarter starting on Tuesday
+ 1.22%
And Citigroup C,
+ 2.11%,
As well as Johnson & Johnson.

Meanwhile, Britain has a self-appointed date to reach a trade agreement with the European Union. The current system runs till the end of the year. UK data shows that the unemployment rate rose to 4.5% in the three months to the end of August, which was higher than expected, but the facade expects a major jump when the furlough program ends in late October.

On stock moves, MorphoSys MOR,
-9.53%

Peacock,
+ 2.01%
Shares fell 9% as the dual-listed biopharmaceutical said it was selling € 325 million convertible bonds.

Rolls Royce RR,
-5.41%
Shares fell 8%, the second day of sharp losses for the troubled engine maker after nearly doubling in value last week.

A Rolls Royce customer, Airbus AIR,
-2.98%,
JPMorgan dropped 3% after underweight from grip on Cazenove. The broker cited a more cautious outlook on air travel and airline profitability, causing it to reduce its consideration on delivery to 10% the following year.

Sse sse,
+ 4.07%
The shares rose 5% after agreeing to sell their 50% stake in two energy-to-idle ventures to Infrastructure Fund, managed by First Centre Investors, for £ 995 million.

    .

Leave a Reply

Your email address will not be published.